Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
American Journal of Hematology|October 2, 2019
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myelomaEven H Rustad, Kristine Misund, Elsa Bernard, et al.
The Journal of Molecular Diagnostics : JMD|March 24, 2023
Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Detailed Description of the Technical Performance, Clinical Utility, and Platform ComparisonKseniya Petrova-Drus, Mustafa Syed, Wayne Yu, et al.
The Journal of Molecular Diagnostics : JMD|August 22, 2025
High-Specificity Detection of UV Mutational Signatures in Circulating Tumor DNA for Diagnostic Classification of Cutaneous and Unknown Primary Tumors Using FoundationOne Liquid CDxDouglas A Mata, Angela A Kou, Andreas M Heilmann, et al.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
The Journal of Clinical Investigation|September 8, 2020
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursorJustin Taylor, Mark Ta Donoghue, Caleb Ho, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Blood|January 10, 2023
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signaturesBenjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, et al.
The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.
JAMA Oncology|April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical TrialOla Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
Pageof 8